By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


SEARCH JOBS

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

About Oncotype DX®
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. With half a million patients tested in more than 80 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com, www.mybreastcancertreatment.org and www.myprostatecancertreatment.org.


Key Statistics


Email:
Ownership: Public

Web Site: Genomic Health, Inc.
Employees:
Symbol: GHDX
 




Segment
Biotechnology





Company News
Genomic Health, Inc. (GHDX) To Present At Bank of America (BAC) Merrill Lynch 2016 Health Care Conference 5/4/2016 8:00:20 AM
Genomic Health, Inc. (GHDX) To Announce First Quarter 2016 Financial Results And Host Conference Call On Wednesday, May 4, 2016 4/27/2016 7:45:02 AM
Genomic Health, Inc. (GHDX) Announces Five-Year Outcomes From International 'PlanB' Study Demonstrating The Clinical Utility Of Oncotype DX In Node-Positive And High-Risk Node-Negative Breast Cancer 3/11/2016 6:14:38 AM
Genomic Health, Inc. (GHDX) Release: German National Cancer Guidelines Distinguish Oncotype DX As First And Only Multi-Gene Breast Cancer Test With 1A Level Of Evidence 3/9/2016 6:32:30 AM
Genomic Health, Inc. (GHDX) To Present At The Cowen and Company 36th Annual Health Care Conference 3/2/2016 7:36:47 AM
Genomic Health, Inc. (GHDX) Announces 2016 Financial Outlook And Provides 2015 Fourth Quarter And Year-End Financial Results 2/11/2016 7:34:39 AM
Genomic Health, Inc. (GHDX) To Announce Fourth Quarter And Year-End 2015 Financial Results And Host Conference Call On Wednesday, February 10, 2016 2/3/2016 7:39:06 AM
Genomic Health, Inc. (GHDX) Announces Plans To Launch Liquid Biopsy Mutation Panel In 2016 1/11/2016 11:33:01 AM
Genomic Health, Inc. (GHDX) Announces Preliminary 2015 Revenue And Confirms 2016 Growth Expectations 1/8/2016 8:59:46 AM
Genomic Health, Inc. (GHDX) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/4/2016 6:58:18 AM
12345678910...
//-->